Is radiotherapy still an option for residual retroperitoneal masses in stage IIC seminoma?
- 28 April 2026
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (10) , 1-7
Abstract
Purpose In patients with clinical stage IIC seminoma, residual retroperitoneal masses are detected in up to 80% of patients after chemotherapy. Lesions < 3 cm are generally monitored; however, the management of patients with residuals > 3 cm remains a matter of debate. Herein, we present a case series of these patients who underwent radiotherapy (RT) and discuss the role of RT in these cases. Methods Three patients with de novo and two patients with relapsed stage IIC seminoma who underwent RT for retroperitoneal residual masses after chemotherapy at two centers between 2014 and 2025 were retrospectively evaluated. All treatment decisions were made by a multidisciplinary board. Results The median age of the patients was 43 (26–47) years, and the median follow-up was 30 (10–120) months. Following radical orchiectomy, all patients received 3–4 cycles of BEP chemotherapy. The median size of the post-chemotherapy residual was 6.5 (3.2–8.5) cm. PET-CT was positive with SUVmax > 3 for all patients. Two patients received only paraaortic RT, three patients received paraaortic + ipsilateral pelvic lymph node RT with a total dose of 25.5 Gy. An additional dose of 10 Gy was prescribed to the residual mass. All treatments were implemented with intensity-modulated radiotherapy (IMRT). Three patients experienced grade 1 nausea. No recurrence or secondary malignancy was detected at final follow-up. Conclusion Radiotherapy may be considered as a potential non-invasive option for managing residual retroperitoneal masses after chemotherapy in stage IIC seminoma, particularly in patients with a high risk of recurrence and in whom retroperitoneal lymph node dissection (RPLND) is anticipated to be associated with morbidity.Keywords
This publication has 33 references indexed in Scilit:
- Very Early Relapse (< 1 year) in de novo Metastatic Seminoma is Associated With Reduced Overall SurvivalClinical Genitourinary Cancer, 2025
- Testicular Germ Cell TumorsJAMA, 2025
- Mini-review: Evaluation and Management of Retroperitoneal Masses in Patients with Testicular CancerEuropean Urology Focus, 2024
- Clinical Outcomes of De Novo Versus Relapsed Early Metastatic Testicular Seminoma Treated With Contemporary Radiation TherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2023
- Global patterns in testicular cancer incidence and mortality in 2020International Journal of Cancer, 2022
- Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Radiotherapy for Post-Chemotherapy Residual Mass in Advanced Seminoma: A Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Risk-adapted ApproachClinical Oncology, 2021
- Retroperitoneal lymph node dissection for testicular seminomas: population-based practice and survival outcomesWorld Journal of Urology, 2018
- Reduzierte Morbidität bei der Resektion von Residualtumoren nach Chemotherapie beim SeminomDer Urologe, 2015
- Survival Analysis of Pure Seminoma at Post-Chemotherapy Retroperitoneal Lymph Node DissectionJournal of Urology, 2014